|
|
|
|
|
|
|
|
|
|
|
|
|
|
Previous: MOLECULAR DEVICES CORP, 10-Q, 2000-08-11 |
Next: PHARMACEUTICAL PRODUCT DEVELOPMENT INC, 10-Q, 2000-08-11 |
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONDENSED CONSOLIDATED BALANCE SHEET AS OF JUNE 30, 2000 AND THE CONSOLIDATED
STATEMENT OF INCOME FOR THE SIX MONTHS ENDED JUNE 30, 2000 AND IS QUALIFIED IN
ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 6-MOS
<FISCAL-YEAR-END> DEC-31-2000
<PERIOD-START> JAN-01-2000
<PERIOD-END> JUN-30-2000
<CASH> 73,392
<SECURITIES> 17,591
<RECEIVABLES> 20,215
<ALLOWANCES> 373
<INVENTORY> 9,998
<CURRENT-ASSETS> 124,517
<PP&E> 12,699
<DEPRECIATION> 6,367
<TOTAL-ASSETS> 137,200
<CURRENT-LIABILITIES> 11,922
<BONDS> 0
0
0
<COMMON> 11
<OTHER-SE> 125,267
<TOTAL-LIABILITY-AND-EQUITY> 137,200
<SALES> 37,375
<TOTAL-REVENUES> 37,375
<CGS> 13,953
<TOTAL-COSTS> 13,953
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 0
<INCOME-PRETAX> 9,808
<INCOME-TAX> 3,776
<INCOME-CONTINUING> 6,032
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 6,032
<EPS-BASIC> 0.60
<EPS-DILUTED> 0.56
</TABLE>
|
|